866933-46-2

Basic information

• Product Name: 1,2-Dihydro-N-[(3-endo)-8-[(2R)-2-hydroxy-3-[methyl(methylsulfonyl)amino]propyl]-8-azabicyclo[3.2.1]oct-3-yl]-1-(1-methylethyl)-2-oxo-3-quinolinecarboxamide
• Synonyms: 1,2-Dihydro-N-[(3-endo)-8-[(2R)-2-hydroxy-3-[methyl(methylsulfonyl)amino]propyl]-8-azabicyclo[3.2.1]oct-3-yl]-1-(1-methylethyl)-2-oxo-3-quinolinecarboxamide;3-QuinolinecarboxaMide, 1,2-dihydro-N-[(3-endo)-8-[(2R)-2-hydroxy-3-[Methyl(Methylsulfonyl)aMino]propyl]-8-azabicyclo[3.2.1]oct-3-yl]-1-(1-Methylethyl)-2-oxo-;TD 5108;Velusetrag;HXLOHDZQBKCUCR-WOZUAGRISA-N
• CAS NO: 866933-46-2
• Molecular Formula: C25H36N4O5S
• Molecular Weight: 504.64214
• Mol File: 866933-46-2.mol

Chemical Properties

• Appearance: /
• Density: 1.34
• CAS DataBase Reference: 1,2-Dihydro-N-[(3-endo)-8-[(2R)-2-hydroxy-3-[methyl(methylsulfonyl)amino]propyl]-8-azabicyclo[3.2.1]oct-3-yl]-1-(1-methylethyl)-2-oxo-3-quinolinecarboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: 1,2-Dihydro-N-[(3-endo)-8-[(2R)-2-hydroxy-3-[methyl(methylsulfonyl)amino]propyl]-8-azabicyclo[3.2.1]oct-3-yl]-1-(1-methylethyl)-2-oxo-3-quinolinecarboxamide(866933-46-2)
• EPA Substance Registry System: 1,2-Dihydro-N-[(3-endo)-8-[(2R)-2-hydroxy-3-[methyl(methylsulfonyl)amino]propyl]-8-azabicyclo[3.2.1]oct-3-yl]-1-(1-methylethyl)-2-oxo-3-quinolinecarboxamide(866933-46-2)

Safety Data

• Hazardous Substances Data: 866933-46-2(Hazardous Substances Data)

Usage

Uses

Used in Medicinal Chemistry:
1,2-Dihydro-N-[(3-endo)-8-[(2R)-2-hydroxy-3-[methyl(methylsulfonyl)amino]propyl]-8-azabicyclo[3.2.1]oct-3-yl]-1-(1-methylethyl)-2-oxo-3-quinolinecarboxamide is used as a compound with potential biological activity for the development of new drugs. Its unique structure, including the quinoline ring and amide group, may contribute to its interaction with biological targets, offering opportunities for the treatment of various diseases.
Used in Drug Development:
In the pharmaceutical industry, 1,2-Dihydro-N-[(3-endo)-8-[(2R)-2-hydroxy-3-[methyl(methylsulfonyl)amino]propyl]-8-azabicyclo[3.2.1]oct-3-yl]-1-(1-methylethyl)-2-oxo-3-quinolinecarboxamide is utilized as a starting point for the design and synthesis of novel therapeutic agents. Its complex molecular architecture allows for modifications and optimizations to enhance its pharmacological properties, such as potency, selectivity, and bioavailability, ultimately leading to the creation of effective medications.

Upstream product

• 866777-83-5 1-isopropyl-2-oxo-1,2-dihydroquinoline-3-carboxylic acid {(1S,3R,5R)-8-aza-bicyclo[3.2.1]oct-3-yl}amide trifluoroacetate 
• 866777-98-2 N-methyl-N-[(S)-2-oxiran-2-ylmethyl]methanesulfonamide 
• 866777-78-8 ((R)-2-hydroxy-3-{3-[(1-isopropyl-2-oxo-1,2-dihydroquinoline-3-carbonyl)amino]-(1S,3R,5R)-8-azabicyclo[3.2.1]oct-8-yl}propyl)methylcarbamic acid tert-butyl ester 
• 124-63-0 methanesulfonyl chloride 
• 158577-01-6 1-isopropyl-2-oxo-1,2-dihydroquinoline-3-carboxylic acid 
• 174486-98-7 1-isopropyl-2-oxo-1,2-dihydro-3-quinolinecarboxylic acid chloride 
• 103718-15-6 2-(isopropylamino)benzaldehyde 
• 28957-72-4 N-benzylnortropinone 
• 106898-71-9 2-isopropylaminobenzyl alcohol 
• 174486-54-5 (1S,3R,5R)-3-[(3-isopropyl-2-oxo-1,2-dihydroquinoline-1-carbonyl)-amino]-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester 
• 542-05-2 acetonedicarboxylic acid 
• 207405-68-3 tert-butyl 3-endo-amino-8-azabicyclo[3.2.1]octane-8-carboxylate 
• 174486-91-0 1-isopropyl-2-oxo-1,2-dihydroquinoline-3-carboxylic acid {(1S,3R,5R)-8-aza-bicyclo[3.2.1]oct-3-yl}amide 
• 5226-51-7 2,2-dimethyl-1,4-dihydro-2H-3,1-benzoxazine 

Relevant articles and documents

Discovery, oral pharmacokinetics and in vivo efficacy of velusetrag, a highly selective 5-HT4 receptor agonist that has achieved proof-of-concept in patients with chronic idiopathic constipation

Utilization of Theravance's multivalent approach to drug discovery towards 5-HT4 receptor agonists with a focus on identification of neutral (non-charged at physiological pH) secondary binding groups is described. Optimization of a quinolone-tr

Prokinetic agent for bowel preparation

The invention provides methods of bowel preparation before a diagnostic, surgical or therapeutic procedure, in particular, bowel preparation before a colonoscopy procedure, using a 5-HT4 receptor agonist as a prokinetic agent.

Crystalline form of a quinolinone-carboxamide compound

The invention provides a crystalline hydrochloride salt of 1-isopropyl-2-oxo-1,2-dihydroquinoline-3-carboxylic acid {(1S,3R,5R)-8-[(R)-2-hydroxy-3-(methanesulfonyl-methyl-amino)propyl]-8-azabicyclo[3.2.1]oct-3-yl}amide or a solvate thereof. The invention also provides pharmaceutical compositions comprising such crystalline salt forms, methods of using such crystalline salt forms to treat diseases associated with 5-HT4 receptor activity, and processes useful for preparing such crystalline salt forms.